WO1998004255A1 - Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases - Google Patents

Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases Download PDF

Info

Publication number
WO1998004255A1
WO1998004255A1 PCT/EP1997/004124 EP9704124W WO9804255A1 WO 1998004255 A1 WO1998004255 A1 WO 1998004255A1 EP 9704124 W EP9704124 W EP 9704124W WO 9804255 A1 WO9804255 A1 WO 9804255A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycine
amino acid
alanine
serine
medicament
Prior art date
Application number
PCT/EP1997/004124
Other languages
English (en)
Inventor
Heinz Schneider
Original Assignee
Novartis Nutrition Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Nutrition Ag filed Critical Novartis Nutrition Ag
Priority to JP10508514A priority Critical patent/JP2000515874A/ja
Priority to CA002260886A priority patent/CA2260886A1/fr
Priority to EP97936676A priority patent/EP0921794A1/fr
Priority to AU39420/97A priority patent/AU716906B2/en
Publication of WO1998004255A1 publication Critical patent/WO1998004255A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the use of certain amino acids in the preparation of a medicament or nutritional formulation with anti-tumor and/or anti-metastatic effect.
  • Cancer is a disease in which individual cells begin by prospering selfishly at the expense of their neighbours but in the end destroy the whole cellular society. Cancer is widely accepted as a disease that is highly dependent on cell proliferation.
  • cell replication is necessary for tumor development at every stage: fixing both spontaneous and chemically-induced mutations in DNA in the initiating step; the clonal expansion of initiated cells in the promotion phase; and providing further stimuli for cell growth in the progression phase.
  • Tumor promoters are substances which are not themselves mutagenic but which cause cancer in tissues previously exposed to a tumor initiator. Tumor promoters are also referred to as non-genotoxic or epigenetic carcinogens, since they do not directly interact with DNA. An increase in DNA synthesis and cell proliferation had been speculated to increase error susceptibility rate for genetic base pairing which can lead to progression of the cancer process.
  • WY- 14,643 is a member of the class of compounds known collectively as peroxisome proliferators which are characterized by increased number and size of peroxisomes as well as associated peroxisomal enzymes in hepatocytes. Additionally, they cause hepatocellular adenoma and carcinoma in rodents to varied degrees. WY- 14,643 is one of the more potent carcinogens in this class causing tumors in 100 % of animals in one year. Although the mechanism by which peroxisome proliferators cause cancer remains unknown, a considerable amount of evidence suggests that they act via non-genotoxic mechanisms involving tumor promotion. Peroxisome proliferators are a group of non-genotoxic carcinogens which include a number of hypolipidemic drugs, solvents, and industrial plasticizers.
  • WY- 14,643 and nafenopin cause a greater number of preneoplastic lesions in livers of older rats than in livers of younger rats suggesting that peroxisome proliferators act as tumor promoters on spontaneously initiated cells which are more numerous in older rats.
  • glycine prevents the increase in hepatocyte proliferation caused by WY- 14,643.
  • WY- 14,643 the increase in peroxisomal ⁇ -oxidation due to WY- 14,643 was not affected by glycine indicating that the pathways responsible for cell proliferation and peroxisome proliferation are distinct.
  • compositions, formulations and diets comprising glycine as well as methods of using glycine.
  • glycine is conveniently employed in free amino acid form, in the form of glycine precursors, in particular alanine or serine, likewise in free amino acid form, in physiologically acceptable salt form of said amino acids, or in form of mixtures of said amino acids and/or physiologically acceptable salts thereof.
  • Glycine is preferably used in free amino acid form, in physiologically acceptable salt form or in the form of a mixture of glycine in free amino acid form with glycine in physiologically acceptable salt form; most preferably glycine is in free amino acid form. Glycine may also be used in the form of dipeptides according to the invention.
  • amino acid of the invention as used hereinafter is meant to refer to glycine, alanine and/or serine, in free amino acid form and/or physiologically acceptable salt form.
  • the present invention therefore provides the use of at least one amino acid selected from the group consisting of glycine, alanine and serine, or physiologically acceptable salts thereof, in the preparation of a medicament or nutritional formulation for the prophylactic and/or therapeutic treatment of tumor growth and/or metastasis.
  • the present invention also provides a method for the prophylactic and/or therapeutic treatment of tumor growth and/or metastasis comprising administering to a human being or other mammal a medicament or nutritional formulation comprising at least one amino acid selected from the group consisting of glycine, alanine, serine, and physiologically acceptable salts of glycine, alanine and serine in an amount which is effective for preventing and/or inhibiting tumor growth and/or metastasis.
  • the invention further provides the use of at least one amino acid selected from the group consisting of glycine, alanine or serine, or physiologically acceptable salts thereof, in the preparation of a medicament or nutritional formulation for inhibiting increased cell proliferation.
  • the present invention still further provides a method for inhibiting increased cell proliferation comprising administering to a human being or other mammal a medicament or nutritional formulation comprising at least one amino acid selected from the group consisting of glycine, alanine, serine, and physiologically acceptable salts of glycine, alanine and serine in an amount which is effective for inhibiting increased cell proliferation.
  • Tumor growth refers to abnormal growth of tissue, which may be benign or malignant, whereby malignant tumors and cancer are used interchangeably herein.
  • the amino acids of the invention are useful in the prophylactic and/or therapeutic treatment of tumors induced by either genotoxic or non-genotoxic carcinogens or both. They are particularly effective in the prophylactic treatment of tumors, particularly for the prophylactic treatment of tumors induced by non-genotoxic carcinogens such as peroxisome proliferators (e.g. hypolipidemic drugs, solvents, and industrial plasticizers) and/or cell proliferators.
  • peroxisome proliferators e.g. hypolipidemic drugs, solvents, and industrial plasticizers
  • cell proliferators e.g. hypolipidemic drugs, solvents, and industrial plasticizers
  • the amino acids of the invention are further particularly useful in the prophylactic and therapeutic treatment of malignant tumors such as liver cancer.
  • the amino acids of the invention are useful in preventing the risk of developing tumors, in promoting tumor regression, in stopping tumor growth and/or in preventing metastasis.
  • the nutritional formulation or medicament may be administered to the patient enterally or parenterally.
  • the enteral administration route is preferred, particularly for subsequent or prophylactic treatment; particularly contemplated enteral administration routes are oral administration, nasal administration and/or tube feeding.
  • the medicament or formulation is conveniently administered in the form of an aqueous liquid.
  • the medicament or formulation in a form suitable for enteral application is accordingly preferably aqueous or in powder form, whereby the powder is conveniently added to water prior to use.
  • the amount of water to be added will depend, inter alia, on the patient's fluid requirements and condition.
  • the medicament or formulation may be so formulated as to deliver to the patient from 1 to 80 g, preferably 1 to 60 g, particularly preferred 20 to 40 g of the amino acid of the invention per 24 hours.
  • the amount of medicament or formulation to be administered depends to a large extent on the patients' specific requirements. Such daily amounts of amino acid of the invention are suitable for treatment of the desired effects as well as for prophylactic/pretreatment.
  • the medicament or formulation comprises a single amino acid of the invention (in the L-configuration)
  • it may be administered to the patient in an amount such that the concentration of that amino acid in the patients' plasma is elevated to between 0.4 and 2.0 mM, preferably from 0.5 to 1.2 mM.
  • concentrations higher than this are anticipated, it is expected that significant clinical effects will be obtained if the concentration of the acid is increased, as a consequence of administration of the formulation or medicament, so that it lies in the range of from 0.6 to 0.9 mM.
  • concentration of the acid is increased, as a consequence of administration of the formulation or medicament, so that it lies in the range of from 0.6 to 0.9 mM.
  • the most preferred amino acid of the invention for incorporation into the medicament or formulation for use according to the invention is glycine or a physiologically acceptable salt thereof.
  • omega-3 polyunsaturated fatty acid where desired in admixture with an omega-6 PUFA
  • a medicament or nutritional formulation comprising an amino acid of the invention in combination with arginine or other physiologically acceptable compound associated with the synthesis of polyamines such as ornithine is preferred.
  • Nucleobase sources suitable for use in combination with the amino acids of the invention comprise or consist of natural nucleobases, nucleosides, nucleotides, RNA, DNA, equivalents thereof and/of mixtures comprising one or more of these compounds.
  • Natural nucleobases include the purines adenine and guanine as well as the pyrimidines cytosine, thymine and uracil. Where the nucleobase source is in the form of free nucleobases, it is preferably uracil.
  • Natural nucleosides include the ribose nucleosides adenosine, guanosine, uridine and cytidine and the deoxyribose nucleosides deoxyadenosine, deoxyguanosine, deoxythymidine and deoxycytidine.
  • Natural nucleotides include phosphate esters of natural nucleosides, such as the monophosphates adenylate (AMP), guanylate (GMP), uridylate (UMP), cytidylate (CMP), deoxythymidiylate (dTMP), deoxycytidylate (dCMP), and diphosphates and triphosphates of natural nucleosides such as ADP and ATP.
  • AMP monophosphates adenylate
  • GMP guanylate
  • UMP uridylate
  • CMP cytidylate
  • dTMP deoxythymidiylate
  • dCMP deoxycytidylate
  • diphosphates and triphosphates of natural nucleosides such as ADP and ATP.
  • a purified nucleobase source such as yeast is preferred. However, other sources such as meat and the like may be used.
  • the nucleobase source is RNA.
  • the invention provides medicaments or nutritional formulations comprising effective amounts of:
  • omega-3 PUFAs where desired in admixture with omega-6 PUFAs (component (b));
  • One unit dose of such medicament or nutritional formulation preferably comprises 1.5 to 80 parts by weight of component (a) in association with the following amounts of one or more components selected from (b) to (d): 0.1 to 20 parts by weight of component (b), 3 to 40 parts by
  • One unit dose of such a medicament or nutritional formulation preferably comprises 1.5 to 80 weight of component (c) and 0.1 to 4.0 parts by weight of component (d).
  • Particularly preferred one unit dose comprises 1.5 to 80 parts by weight of component (a) in association with the following amounts of one or more components selected from (b) to (d): 2 to 5 parts by weight of component (b), 7.5 to 20 parts by weight of component (c) and 1.7 to 2.0 parts by weight of component (d).
  • the amount of components (a) to (d) administered daily will conveniently correspond to 1.5 to 80 g for component (a), 0.1 to 20 g, preferably 2 to 5 g, for component (b), 3 to 40 g, preferably 7.5 to 20 g, for component (c) and 0.1 to 4.0 g, preferably 1.7 to 2.0 g, for component (d).
  • RNA Ribonucleic acid
  • nucleobases one weight unit of nucleobases is regarded to be equivalent to 2.5 to 3.0 weight units of RNA, DNA, nucleosides or nucleotides.
  • medicaments or nutritional formulations comprising an amino acid of the invention in combination with one or more of the above-mentioned components (b), (c) and (d) are used, such medicaments or nutritional formulations will conveniently comprise in one unit dose
  • Preferred medicaments or nutritional formulations comprise in one unit dose:
  • the medicaments or nutritional formulations of the invention comprise component (a) in combination with component (c) at a weight ratio of 1 :2 to 4: 1 , particularly preferred at a weight ratio of 1 : 1 to 2: 1.
  • medicaments or nutritional formulations comprise in one unit dose:
  • Omega-3 PUFAs are conveniently protected against peroxidation.
  • Physiologically acceptable ways of protecting omega-3 PUFAs against peroxidation include physiologically acceptable micro-encapsulation of omega-3 PUFAs and the use of physiologically acceptable antioxidants.
  • a typical example suitable for use as physiologically acceptable micro-encapsulation agents is starch.
  • the micro-encapsulation can be effected in a manner known per se.
  • the micro- encapsules may be coated in a manner known per se, by physiologically acceptable coating agents such as Gum Arabic.
  • antioxidants suitable for use in the method of the invention include antioxidant vitamins such as Vitamin C, Vitamin E or mixtures thereof.
  • the amount of antioxidant added should be sufficient to prevent peroxidation of the omega-3 PUFAs. Such amounts can be easily calculated. In general, for convenience, any antioxidants employed to prevent peroxidation, will be employed in excess. It will be appreciated that the presence of any other agent administered in association with the omega-3 PUFAs may require adjustment of the amount of antioxidant to be employed.
  • the omega-3 PUFAs may be employed in a form suitable for the physiological supply of omega-3 PUFAs, e.g. in free acid form, in triglyceride form, or in the form of physiologically acceptable natural sources of omega-3 PUFAs.
  • natural sources include linseed oil and fish oils such as menhaden oil, salmon oil, mackerel oil, tuna oil, cod-liver oil and anchovy oil.
  • Said natural sources, in particular, the fish oils comprise substantial amounts of omega- 3 fatty acids.
  • said triglycerides may comprise esters with other physiologically acceptable fatty acids.
  • Preferred omega-3 PUFAs include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in free acid form, in triglyceride form or in form of natural sources having a high EPA and/or DHA content.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • such a medicament will comprise from 1 to 99 g of the amino acid of the invention per lOOg.
  • a formula diet accordingly may comprise a source of carbohydrates, lipids fat (fat source) and protein (nitrogen source), and at least one amino acid selected from the group consisting of glycine, L-alanine and L-serine, or physiologically acceptable salts thereof, characterized in that the acid or salt is present in the formula diet in an amount of about 0.5 to lOg per lOOg.
  • the formula diet will preferably further comprise other nutritionally advantageous components such as vitamins, minerals, trace elements, fibers (preferably soluble fibers).
  • suitable nitrogen sources include nutritionally acceptable proteins such as soy bean or whey derived proteins, caseinates, and/or protein hydrolysates.
  • suitable carbohydrate sources include sugars such as maltodextrins.
  • suitable fat sources include triglycerides, as well as di- and monoglycerides.
  • vitamins suitable for incorporation into the medicament or formulation of the invention include Vitamin E, Vitamin A, Vitamin D, Vitamin K, folic acid, thiamin, riboflavin, Vitamin B-, B 2 , B 6 and B ⁇ 2 , niacin, biotin and panthotenic acid in nutritionally acceptable form.
  • Examples of mineral elements and trace elements suitable for incorporation into the medicament or formulation include sodium, potassium, calcium, phosphorous, magnesium, manganese, copper, zinc, iron, selenium, chromium, and molybdenum in nutritionally acceptable form.
  • the medicament or formulation will preferably comprise beta-carotene (Vitamin A), Vitamin E, Vitamin C, thiamine, Vitamin B ⁇ , choline, selenium and zinc in nutritionally acceptable form.
  • soluble fiber refers to fibers which are able to undergo substantial fermentation in the colon ultimately to produce short chain fatty acids.
  • suitable soluble fibers include pectin, guar gum, locust bean gum, xanthan gum which may optionally be hydrolysed.
  • pectin pectin
  • guar gum locust bean gum
  • xanthan gum which may optionally be hydrolysed.
  • the total amount of soluble fibre per day will conveniently lie in the range of from 3 to 30g.
  • omega-3 PUFAs may be administered in higher amounts than those indicated hereinabove, and that such higher amounts will in general not impair the desired effect or provoke undesired side effects.
  • Compounds particularly suitable for use as component (c) in the formulation of the invention include L-arginine and L-ornithine, most preferably L-arginine.
  • Component (c) may be employed in free form, physiologically acceptable salt form, e.g. in the form of a salt with phosphoric acid, citric acid, tartaric acid, fumaric acid, adipic acid or lactic acid, or in small peptide form.
  • L-arginine in free form is employed.
  • small peptides refers to peptides having from 2 to 6, preferably from 2 to 4 amino acids.
  • omega-3 PUFAs will conveniently be administered in the form of fish oils, protected or not against peroxidation.
  • fish oils also comprises omega-6 PUFAs.
  • Omega-6 PUFAs have also a favorable effect on the immune response and on the resistance to infection upon surgery. Accordingly, diets of the invention will conveniently further comprise omega-6 PUFAs.
  • the omega-6 PUFAs may be in free acid form or in a form suitable for the physiological supply of omega-6 PUFAs, e.g. in triglyceride form.
  • Examples of omega-6 PUFAs particularly appropriate for use according to the invention include linoleic acid and arachidonic acid, linoleic acid being most preferred.
  • suitable omega-6 PUFA sources are known in the art. They include fish oils and vegetable oils. Examples of omega-6 PUFA sources having a high linoleic acid content such as safflower oil, sunflower oil, soya oil, cotton oil and corn oil.
  • omega-6 PUFAs administered in the range of from 1.5 to 5.0 g will in general suffice to attain a favorable effect.
  • One unit dose of the medicaments or nutritional formulation defined above may accordingly further contain 1.5 to 5 parts by weight of omega-6 PUFAs.
  • omega-6 PUFAs further components may be added to the diets of the invention and may have a beneficial effect on the activity of the amino acid of the invention.
  • beneficial components are omega-9 PUFAs.
  • a preferred natural source for such fatty acid mixtures are fish oils.
  • the fish oils will, in oral application forms, preferably be used in encapsulated form.
  • the amount of energy supplied by it should not be too excessive, in order not to unnecessarily suppress the patients appetite.
  • the supplement should conveniently comprise energy sources in an amount supplying from 150 to 1000 Kcal/day, preferably 250-500 Kcal/day.
  • the diets of the invention will conveniently supply from 600 to 1500 Kcal/day.
  • the contribution of the nitrogen source, carbohydrate source and lipid source to the total daily caloric may vary within wide ranges.
  • the carbohydrate source provides for 40 to 70 % of the total energy supply and, the nitrogen and fatty acid source each for 15 to 30 % of the total energy supply of the formulation.
  • the diet of the invention will conveniently be administered in aqueous liquid form in volumes in the range of from 500 ml to 3000 ml.
  • the administration may be in powder or liquid form.
  • the supplement will conveniently be administered in the form of unit doses suitable for administration of the supplement 1 to 4 times per day.
  • the diets of the invention comprise energy sources, it is appropriate not to supply more than 1500 Kcal/day.
  • the amino acid of the invention will conveniently be administered parenterally.
  • Typical administration forms suitable for such acute treatment are e.g. the aqueous solutions disclosed hereinbelow.
  • Typical pharmacologically acceptable formulation forms for oral administration will further comprise pharmacologically acceptable diluents, carriers, vitamins, spices, pigments and/or other adjuvants well known to the skilled person to be suitable for incorporation into such formulation.
  • the diets and formulations of the invention may be obtained in a manner known per se, e.g. by admixing the ingredients.
  • Typical formulations suitable for use according to the invention include aqueous solutions consisting essentially of 0.1 % to 90 % by weight of at least one amino acid selected from the group consisting of glycine, alanine and serine, and pharmaceutically acceptable salts thereof, the balance being distilled water.
  • the amino acid of the invention may be present in a concentrated form of the solution in an amount of from 15 to 90% (by weight of the solution). Concentrated solutions are suitable for dilution to application forms or for use in acute treatment. Application forms having a lower content (e.g. 0.1 to 5 %) of the amino acid of the invention will in general be indicated for prophylactic purposes; concentrated forms of the solution having a higher content (e.g. 5 % to 40 % by weight) of amino acid of the invention will in general be more suitable for acute treatment.
  • formulations suitable for inclusion in the medicament or formulation of the invention, in particular for parenteral application include infusion solutions such as Ringer's injection solution, lactated Ringer's injection solution, crystalloids, colloids or other plasma substitutes, in association or enriched with about 0.1 to 5.0g per liter infusion solution of glycine, serine and/or alanine.
  • infusion solutions such as Ringer's injection solution, lactated Ringer's injection solution, crystalloids, colloids or other plasma substitutes, in association or enriched with about 0.1 to 5.0g per liter infusion solution of glycine, serine and/or alanine.
  • Ringer's injection solution is a sterile solution, containing from 3.23 to 3.54g of sodium (equivalent to from 8.2 to 9.0g of sodium chloride), from 0.149 to 0.165 of potassium (equivalent to from 0.285 to 0.315g of potassium chloride), from 0.082 to 0.098g of calcium (equivalent to from 0.3 to 0.36g of calcium chloride, in the form of CaCl 2 -2H 2 O), from 5.23 to 5.80g of chloride (as NaCl, KCl and CaCl 2 -2H 2 O) and water in sufficient quantity to give 1000 ml solution.
  • Lactated Ringer's Injection solution is a sterile solution containing from 2.85g to 3.15g sodium, as chloride and lactate), from 0.141 to 0.173g of potassium (equivalent to from 0.27g to 0.33g of potassium chloride), from 0.049 to 0.060g calcium (equivalent to from 0.18g to 0.22g of CaCl 2 .2H 2 O), from 2.31g to 2.61g of lactate, from 3.68 to 4.08g of chloride (as NaCl, KCl and CaCl 2 -2H 2 O) and water in sufficient quantity to give 1000 ml solution.
  • crystalloids and colloids in connection with fluid therapy are known in the art. They include plasma substitutes such as Haemaccel (polygeline based) and Gelofusine (gelatin based).
  • mice were fed either control or glycine diet for three days.
  • rats were treated with either 100 mg/kg WY- 14,643 or olive oil control vehicle (i.g.). Twenty-four hours later, all rats were given 100 mg/kg 5-bromo-2'-deoxyuridine (BrdU, from Sigma) i.p. to label proliferating hepatocytes and were sacrificed one hour later.
  • NrdU 5-bromo-2'-deoxyuridine
  • rats were fed either control or glycine diet for three days; then half of each group was switched to diet containing 0.1 % WY-14,643 for three weeks. During the last three days, all rats were given drinking water containing BrdU (80 mg/100 mL) to label proliferating hepatocytes.
  • a peroxidase labeled polymer conjugated to goat anti-rabbit and goat anti-mouse was applied and allowed to incubate for 10 minutes at room temperature followed by 3,3 -diaminobenzidine in a buffered solution containing hydrogen peroxide for 8 minutes (DAKO Envision System Peroxidase). Sections were rinsed twice with phosphate buffered saline containing 1 % Tween 20 after each incubation. Slides were counterstained with hematoxylin and proliferating cells were identified from brown staining. Cell proliferation was quantitated by counting the percentage of BrdU-positive cells in 10 random high power fields.
  • Acyl CoA oxidase is an accepted measure of induction of peroxisomes. It was measured as formaldehyde formed from hydrogen peroxide generated by peroxisomal ⁇ -oxidation by coupling hydrogen peroxide with the peroxidation of methanol via catalase. Liver samples were homogenized in 10 volumes of 0.25 M sucrose buffer.
  • reaction mixture (pH 8.3) cont-aining 22.2 mg palmitate, 400 ⁇ L methanol, 7.7 mg CoA, 137.8 mg ATP, 40.7 mg MgCl 2 , 10 ⁇ L Triton X-100, 13,3 mg NAD + , 90 mg fatty acid free BSA, and 402,9 mg niacinamide (per 100 mL buffer) was warmed to 37° C.
  • the reaction was started by adding 200 ⁇ L of homogenate to 1.4 mL of reaction buffer and was terminated after 10 minutes with 40 % TCA. TCA was added before homogenate to the blanks.
  • the solution was centrifuged to pellet the protein and 0.5 ml of the supernatant was added to 0.2 ml of the Nash Reagent to measure formaldehyde. After 60 minutes of incubation at 37° C, absorbance of samples was read at 405 nm. Protein concentration in the homogenate was determined by the method of Lowry.
  • Apoptotic bodies were identified based on morphological features of hematoxylin and eosin stained liver sections.
  • the features used to determine apoptotic cells were condensation of cytoplasm, accumulation of condensed chromatin at the nuclear membrane, and fragmentation of the nucleus and cell, giving rise to apoptotic bodies which were phagocytosed by neighboring cells.
  • the apoptotic rate is expressed as the percentage of apoptotic cells counted in 10 random high power fields (1000 hepatocytes counted per slide).
  • Results .are reported as means +_ s.e.m. for n 4 or 5 in each group. Treatment groups were compared using one-way ANOVA and Student-Newman-Keuls post-hoc tests, where appropriate.
  • WY-14,643 (100 mg/kg) increased cell proliferation almost 8-fold in normally quiescent hepatocytes 24 hours after administration from 0.7 + 0.3 % to 5.1 +_0.3 %. While the glycine diet did not affect basal rates of hepatocyte proliferation, feeding the diet containing 5 % glycine for three days prior to treatment with WY-14,643 resulted in an increase in cell replication to values of only 1.9 + 0.4 %. This value was not significantly different from either the control or glycine basal rates of cell proliferation but was significantly less than the 8-fold increase in hepatocyte replication characteristically caused by WY- 14,643.
  • a defining characteristic of all peroxisome proliferators is an induction of peroxisome specific enzymes that follows their administration.
  • Acyl CoA oxidase the hydrogen peroxide producing enzyme catalyzing the rate limiting step of peroxisomal ⁇ -oxidation, reaches peak values which are 8-fold greater than controls after 18 days of treatment with WY- 14,643, but increases can be detected within one day.
  • the glycine diet had no effect on basal acyl CoA oxidase activity and surprisingly did not prevent the increase in acyl CoA oxidase due to WY- 14,643.
  • WY-14,643 Peroxisome proliferation after 3 weeks of treatment with WY-14,643 was even more extensive. WY- 14,643 caused a 6-fold increase in acyl CoA oxidase activity, an increase which was not prevented by the addition of glycine to the diet. This interesting finding further supports the idea that peroxisome proliferation and cell proliferation are not tightly linked events.
  • the liver to body weight ratio for rats fed the control powder diet was about 5.1 + 0.6 % which is slightly higher than the 4-4.5 % for rats fed chow diet.
  • Glycine-fed rats did not differ from controls while the WY- 14,643 diet caused a significant increase in liver to body weight ratio of about 70 %, a phenomenon not prevented by glycine.
  • the addition of 5 % glycine to the WY- 14,643 diet prevented the increase in gross liver size caused by WY- 14,643.
  • the WY- 14,643 diet results in an average liver size that is about 33 % larger than control and glycine while the addition of glycine to the WY-14,643 diet reduced livers to the size of controls.
  • Replicating hepatocytes were determined as cells containing brown nuclei.
  • Four BrdU positive cells were seen in the liver from a WY-14,643-treated rat in the three week study. However, BrdU-positive cells were rarely detected in livers from control, glycine or WY- 14,643 + glycine rats.
  • Basal rates of cell proliferation control diet
  • WY- 14,643 increased hepatocyte replication about 5-fold.
  • the glycine diet resulted in rates of cell proliferation that did not differ from control, while the addition of glycine to the WY- 14,643 diet completely prevented the increase in hepatocyte replication caused by WY- 14,643 alone after three weeks.
  • glycine clearly prevents both early and sustained increases in cell replication due to WY- 14,643. Since peroxisome proliferators such as nafenopin have been shown to inhibit apoptosis, which could contribute to an increase in liver size due to exposure to these chemicals, rates of apoptosis were also determined in livers from the three week study. The percentage of apoptotic cells ranges from 0.20% to 0.35% and were not significantly different for any treatment group. Therefore, changes in apoptosis are not a major contributor to changes in liver size due to WY- 14,643.
  • TNF ⁇ has been shown to be involved in WY-14,643-induced cell proliferation; therefore, in order to determine if the glycine containing diet was preventing TNF ⁇ expression in response to WY- 14,643, immunohistochemical staining for TNF ⁇ was performed. Control levels of TNF ⁇ expression in liver sections were 0.4% of the total area of liver tissue and 0.7% in livers from rats fed the glycine containing diet. Feeding WY- 14,643 in the diet for three weeks increased staining for TNF ⁇ 2-fold, and this increase was largely prevented by the glycine- containing diet.
  • Glycine prevents increases in hepatocyte proliferation due to WY-14,643
  • WY- 14,643 unlike less carcinogenic peroxisome proliferators such as DEHP increases hepatocyte replication for as long as the compound is administered.
  • three weeks of dietary glycine caused a 50% reduction in basal levels of cell proliferation compared to control. Glycine diet did not prevent peroxisome proliferation due to WY- 14,643 at either 24 hours or 3 weeks which supports the hypothesis that peroxisome proliferation and cell proliferation occur via different mechanisms.
  • compositions MM stands for “mineral mixture”
  • SM for "trace element mixture”
  • VM for "vitamin mixture”.
  • the composition of these three mixtures is as follows:
  • Vitamin B 12 0.1% 0.30
  • composition I Comprising Glycine
  • composition II Comprising Glycine
  • composition Comprising Glycine and Arginine
  • composition Comprising Glycine and RNA
  • Composition Comprising Glycine, Arginine and Fish Oil ( ⁇ -3 fatty acids)
  • composition Comprising Glycine, Ai
  • composition Comprising Glycine, RNA and Fish Oil ( ⁇ -3 fatty acids)
  • Composition Comprising Glycine, Arginine, RNA and Fish Oil ( ⁇ -3 fatty acids)
  • fish oil is a natural source for omega-3 PUFAs whereas sunflower oil is a natural source for omega-6 PUFAs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une méthode destinée au traitement prophylactique et/ou thérapeutique de la croissance tumorale et/ou des métastases, comprenant l'administration, à un être humain ou à un autre mammifère, d'un médicament ou d'une formulation nutritionnelle comportant au moins un acide aminé sélectionné dans le group constitué par la glycine, l'alanine, la sérine, et des sels de glycine physiologiquement acceptables, l'alanine et la sérine étant présentes en quantité efficace en vue de la prévention et/ou de l'inhibition de croissance tumorale et/ou des métastases. L'invention concerne également une méthode d'inhibition de la prolifération cellulaire accrue, comprenant l'administration, à un être humain ou à un autre mammifère, d'un médicament ou d'une formulation nutritionnelle comportant au moins un acide aminé sélectionné dans le groupe constitué par la glycine, l'alanine, la sérine, et des sels de glycine physiologiquement acceptables, l'alanine et la sérine étant présentes en quantité efficace en vue de l'inhibition de la prolifération cellulaire accrue.
PCT/EP1997/004124 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases WO1998004255A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP10508514A JP2000515874A (ja) 1996-07-30 1997-07-29 アミノ酸組成物、ならびに腫瘍の成長および転移の処置におけるその使用
CA002260886A CA2260886A1 (fr) 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases
EP97936676A EP0921794A1 (fr) 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases
AU39420/97A AU716906B2 (en) 1996-07-30 1997-07-29 Amino acid composition and use thereof in treating tumor growth and metastasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69047596A 1996-07-30 1996-07-30
US08/690,475 1996-07-30

Publications (1)

Publication Number Publication Date
WO1998004255A1 true WO1998004255A1 (fr) 1998-02-05

Family

ID=24772606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/004124 WO1998004255A1 (fr) 1996-07-30 1997-07-29 Composition a base d'acides amines et utilisation de celle-ci dans le traitement de la croissance tumorale et des metastases

Country Status (6)

Country Link
EP (1) EP0921794A1 (fr)
JP (1) JP2000515874A (fr)
AU (1) AU716906B2 (fr)
CA (1) CA2260886A1 (fr)
ID (1) ID19618A (fr)
WO (1) WO1998004255A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882451A1 (fr) * 1997-06-05 1998-12-09 Novartis Nutrition AG Glycine pour la prévention ou le traitement du rejet de greffes
KR100932520B1 (ko) * 2002-10-31 2009-12-17 박래옥 항암제 조성물
EP2135604A1 (fr) * 2007-03-26 2009-12-23 Hirofumi Matsui Préparation de perfusion pour patient souffrant du cancer
WO2011127039A1 (fr) * 2010-04-05 2011-10-13 Abbott Laboratories Liquides nutritionnels de longue conservation comprenant de la bêta-alanine
WO2015003021A3 (fr) * 2013-07-01 2015-10-29 The Trustees Of Princeton University Compléments alimentaires et composition pour traiter le cancer
US10729157B2 (en) 2004-11-02 2020-08-04 Oragenics, Inc. Methods for regulating weight and size of animals
CN114947139A (zh) * 2022-04-28 2022-08-30 成都尚医信息科技有限公司 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014077289A1 (fr) * 2012-11-15 2014-05-22 株式会社日本生物製剤 Agent anticancéreux

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB818170A (en) * 1957-12-30 1959-08-12 Edward Yerxa Domina Improvements in preparation for the treatment of non-tumorous prostatic hypertrophy
GB2022998A (en) * 1978-06-14 1979-12-28 Beres J Pharmaceutical composition for the treatment of neoplastic and other diseases
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
JPS6248622A (ja) * 1985-08-28 1987-03-03 Grelan Pharmaceut Co Ltd 癌転移抑制剤
EP0560989A1 (fr) * 1991-10-07 1993-09-22 Otsuka Pharmaceutical Factory, Inc. Preparation enterique destinee au traitement du cancer
WO1996025861A1 (fr) * 1995-02-23 1996-08-29 Novartis Nutrition Ag Compositions d'acides amines et leur utilisation dans la nutrition clinique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB818170A (en) * 1957-12-30 1959-08-12 Edward Yerxa Domina Improvements in preparation for the treatment of non-tumorous prostatic hypertrophy
GB2022998A (en) * 1978-06-14 1979-12-28 Beres J Pharmaceutical composition for the treatment of neoplastic and other diseases
GB2029220A (en) * 1978-09-04 1980-03-19 Otsuka Pharma Co Ltd Amino acid solutions for patients with cancers
JPS6248622A (ja) * 1985-08-28 1987-03-03 Grelan Pharmaceut Co Ltd 癌転移抑制剤
EP0560989A1 (fr) * 1991-10-07 1993-09-22 Otsuka Pharmaceutical Factory, Inc. Preparation enterique destinee au traitement du cancer
WO1996025861A1 (fr) * 1995-02-23 1996-08-29 Novartis Nutrition Ag Compositions d'acides amines et leur utilisation dans la nutrition clinique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 106, no. 25, 22 June 1987, Columbus, Ohio, US; abstract no. 209188u, page 222; column 209186; XP002048271 *
DATABASE MEDLINE XP002048272 *
ELDRIFGE: "Measurment of chemically induced cell proliferation in rodent liver and kidney : a comparison of 5-bromo-2'-deoxyuridine and [3H] thymidine administered by injection or osmotic pump", CARCINOGENESIS, vol. 11, no. 12, December 1990 (1990-12-01), pages 2245 - 2251, XP002048269 *
ENOMOTO: "Induction of a novel calcium-dependent serine protease in rat liver treated with various promoters of liver carcinogenesis", TOXICOL. PATHOL., vol. 15, no. 1, 1987, pages 73 - 77 *
IKEJIMA: "Induction of a novel calcium-dependent serine protease in rat liver treated with various promoters of liver carcinogenesis", AM. J. PHYSIOL., vol. 271, no. 1pt1, July 1996 (1996-07-01), pages 97 - 103 *
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 *
ROSE: "Dietary glycine prevents increases in hepatocyte proliferation caused by the peroxisome proliferator WY-14,643", CHEM. RES. TOXICOL., vol. 10, no. 10, October 1997 (1997-10-01), pages 1198 - 1204, XP002048270 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882451A1 (fr) * 1997-06-05 1998-12-09 Novartis Nutrition AG Glycine pour la prévention ou le traitement du rejet de greffes
KR100932520B1 (ko) * 2002-10-31 2009-12-17 박래옥 항암제 조성물
US10729157B2 (en) 2004-11-02 2020-08-04 Oragenics, Inc. Methods for regulating weight and size of animals
EP2135604A1 (fr) * 2007-03-26 2009-12-23 Hirofumi Matsui Préparation de perfusion pour patient souffrant du cancer
EP2135604A4 (fr) * 2007-03-26 2011-08-03 Hirofumi Matsui Préparation de perfusion pour patient souffrant du cancer
WO2011127039A1 (fr) * 2010-04-05 2011-10-13 Abbott Laboratories Liquides nutritionnels de longue conservation comprenant de la bêta-alanine
WO2015003021A3 (fr) * 2013-07-01 2015-10-29 The Trustees Of Princeton University Compléments alimentaires et composition pour traiter le cancer
US11147784B2 (en) 2013-07-01 2021-10-19 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
CN114947139A (zh) * 2022-04-28 2022-08-30 成都尚医信息科技有限公司 一种影响肿瘤生长的氨基酸组合物、功能性食品及其应用

Also Published As

Publication number Publication date
JP2000515874A (ja) 2000-11-28
CA2260886A1 (fr) 1998-02-05
ID19618A (id) 1998-07-23
AU3942097A (en) 1998-02-20
AU716906B2 (en) 2000-03-09
EP0921794A1 (fr) 1999-06-16

Similar Documents

Publication Publication Date Title
CA2499199C (fr) Compositions nutritionnelles enrichies aux leucines
EP0810829B1 (fr) Compositions d'acides amines et leur utilisation dans la nutrition clinique
JP3908785B2 (ja) 微小循環の調節方法
SK106594A3 (en) Nutrituve supplement
KR20060134181A (ko) 하이드록시메틸부티레이트 조성물 및 이의 용도
JP3287842B2 (ja) 免疫刺激剤としてのアルギニンの用途
US6048543A (en) Amino acid compositions and use thereof in clinical nutrition
KR0172193B1 (ko) 암 치료용 경장제제
EP2993992A1 (fr) Composition nutritionnelle pour améliorer la fonction cérébrale dans la phénylcétonurie
US6013273A (en) Treatment of endotoxic shock
AU716906B2 (en) Amino acid composition and use thereof in treating tumor growth and metastasis
US6096785A (en) Amino acid compositions and use thereof in treating renal dysfunction
JPH07258075A (ja) 免疫応答を改善する方法
CA2227978A1 (fr) Immuno-modulation a l'aide d'amino-acides
JPH03204814A (ja) 腎不全用経口アミノ酸製剤
US6864230B2 (en) Glutamine rich dietary composition
JP3914585B2 (ja) マクロファージ一酸化窒素産生亢進剤
MXPA97006140A (en) Compositions of amino acids and the use of them in nutrition clin
ZA200501922B (en) Leucine-enriched nutritional compositions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997936676

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2260886

Country of ref document: CA

Ref country code: CA

Ref document number: 2260886

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997936676

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997936676

Country of ref document: EP